COntinue the SaMe systemic therapy after local ablative therapy for Oligo progression in metastatic breast cancer - the COSMO study - COSMO

ederlands Kanker Instituut0 个研究点目标入组 118 人开始时间: 待定最近更新: 2024年9月9日

适应症

试验速览

暂无简介。

•o Histologically confirmed infiltrating breast cancer
•o MBC according to TNM-staging
•o Oligoprogression defined as one or two distant metastatic lesions, limited to
•o Oligoprogression should occur during first- or second-line systemic therapy
•o Patients should be on systemic therapy for at least 6 months without prior
•evidence of progressive disease.
•o Lesion(s) must be amenable to resection, radiotherapy or percutaneous
•ablation with the intent of local obliteration.
•o Age >=18
•o World Health Organization (WHO) Performance Status 0 or 1
•o Signed written informed consent before patient registration according to
•ICH/GCP, and national/local regulations

•o Having received more than two lines of systemic therapy for MBC
•o Prior or concurrent other invasive malignancy except basal cell carcinoma of
•the skin, unless the other malignancy was treated >=5 years ago with curative
•intent without the use of chemotherapy or radiation therapy
•o Current pregnancy or breastfeeding. Women of childbearing potential must use
•adequate contraceptive protection
•o Presence of any medical condition that would place the patient at unusual risk
•o Presence of any psychological, familial, sociological, or geographical
•condition potentially hampering compliance with the study protocol and
•follow-up schedule

发起方

ederlands Kanker Instituut